

Appl. No. : 09/221,931  
Filed : December 28, 1998

18. The method according to Claim 11, wherein the catechin is epigallocatechin gallate, epigallocatechin, epicatechin gallate, or epicatechin.

19. The method according to Claim 11, wherein the telomerase inhibitor further comprises pharmaceutically acceptable carrier or diluent.

D2 20. (Amended) The method according to Claim 11, wherein the telomerase inhibitor comprises the catechin in an amount of 90 to 95% by weight.

21. A method according to claim 17, wherein the green tea extract contains epigallocatechin gallate in an amount of at least 10 wt%.

**Please add the following new claims:**

22. (New) The method according to claim 11, wherein an effective amount of the telomerase inhibitor is administered to a human subject having the cells exhibiting telomerase activity to contact the cells with the catechin.

D3 23. (New) The method according to claim 22, wherein the concentration of the catechin contacting the cells is selected from effective concentrations including 15  $\mu$ M.

24. (New) The method according to claim 22, wherein the telomerase inhibitor is topically administered.

25. (New) The method according to either of claims 23 or 24, wherein the telomerase inhibitor is topically administered by injection or plaster.

**REMARKS**

Claims 11 and 20 have been amended. New claims 22-25 are added. Claims 11, and 17-25 are now pending in this application. Support for the amendments is found in the existing claims and the specification as discussed below. Accordingly, the amendments do not constitute